JLK Signs Contract with Prof. Gene Sung's Team at University of Southern California Hospital... "5th Hub Hospital This Year"

JLKE, which is expanding its local base hospitals through an aggressive entry strategy into the U.S. market, has signed its fifth comprehensive medical consultant contract with Professor Gene Sung's team at the Keck School of Medicine of USC located in Los Angeles.

JLKE (CEO Dongmin Kim), the first listed medical AI company, announced on the 11th that it secured a foothold in the western U.S. region by signing a contract with Professor Gene Sung and his team at the Keck School of Medicine of USC, the oldest private university in California.

Professor Gene Sung serves as the head of the neurocritical care and stroke division at the Keck School of Medicine of USC. He participated as a founding member of the Neurocritical Care Society and held various positions including secretary, treasurer, vice president, and president from 2005 to 2013. From 2004 to 2012, he also served as associate editor of Neurocritical Care and authored or co-authored over 100 publications.

The Keck School of Medicine of USC is recognized as one of the top institutions for medical education and research in the United States. Established in 1885, it boasts a long and prestigious history and is considered the oldest medical school in California. It is also known for its outstanding research achievements, holding leading positions in fields such as cancer, neuroscience, cardiovascular diseases, and regenerative medicine.

With this contract, the company has come closer to its goal of establishing base hospitals in key regions of the U.S. JLKE, which has secured base hospitals in the central, eastern, and western U.S. as well as Canada this year, now has a total of five bases and expects to successfully conclude contracts with 10 large base hospitals within the year.

Professor Gene Sung, who joined JLKE, stated, "Through this contract with JLKE, I expect to confirm the significant role of artificial intelligence in neurocritical care and stroke diagnosis and treatment procedures." He added, "I will devote my efforts to enhancing JLKE AI solutions' recognition in the U.S. through actual clinical cases and expanding a broad sales network."

JLKE CEO Dongmin Kim said, "I am deeply moved to share the news of consecutive contracts with large base hospitals for a successful early landing in the U.S. market." He continued, "By collaborating with esteemed scholar Professor Gene Sung in the fields of neurocritical care and stroke, we will focus on securing meaningful and remaining base hospitals to firmly establish a forward base for dominating the U.S. market."